Gavin Churchyard

Aurum Institute

Group Chief Executive Officer

Prof. Gavin Churchyard (MBBCh), MMED (Int Med), FCP (SA), FRCP (Edin), PhD) is a specialist physician, internationally renowned for his contributions in tuberculosis (TB) research. Prof Churchyard is the founder and Group Chief Executive Officer of the Aurum Institute, an independent, not for profit, proudly South African, public benefit organization that focuses on TB and HIV technical assistance, service delivery, and research. Prof Churchyard is an Honorary Professor at the University of Witwatersrand, University of Cape Town and the Department of Medicine in the Vanderbilt University School of Medicine. Prof Churchyard is the Chair of the AIDS Clinical Trials Group (ACTG) Transformative Science Group for TB, Chair of the NIH/DIADS funded Cross-network TB vaccine and Immunology Working Group, and a member of the ACTG Scientific Advisory Steering Committee (SASC).  He has extensive clinical trials experience and has conducted numerous TB treatment, TB vaccine, TB preventive therapy, TB diagnostics and Host Directed Therapy for TB trials. Prof Churchyard’s investigator-initiated studies has involved large, multisite and often complex studies in South Africa and internationally. Prof Churchyard has published widely in the fields of TB and HIV.

Gavin Churchyard

Aurum Institute

Group Chief Executive Officer

Prof. Gavin Churchyard (MBBCh), MMED (Int Med), FCP (SA), FRCP (Edin), PhD) is a specialist physician, internationally renowned for his contributions in tuberculosis (TB) research. Prof Churchyard is the founder and Group Chief Executive Officer of the Aurum Institute, an independent, not for profit, proudly South African, public benefit organization that focuses on TB and HIV technical assistance, service delivery, and research. Prof Churchyard is an Honorary Professor at the University of Witwatersrand, University of Cape Town and the Department of Medicine in the Vanderbilt University School of Medicine. Prof Churchyard is the Chair of the AIDS Clinical Trials Group (ACTG) Transformative Science Group for TB, Chair of the NIH/DIADS funded Cross-network TB vaccine and Immunology Working Group, and a member of the ACTG Scientific Advisory Steering Committee (SASC).  He has extensive clinical trials experience and has conducted numerous TB treatment, TB vaccine, TB preventive therapy, TB diagnostics and Host Directed Therapy for TB trials. Prof Churchyard’s investigator-initiated studies has involved large, multisite and often complex studies in South Africa and internationally. Prof Churchyard has published widely in the fields of TB and HIV.